Retatrutide Dosage Calculator: mg to mL to Syringe Units
REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn
Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy
Citations verified against PubMed · Published: 2026-09-07 · Last updated: 2026-09-07
Retatrutide (LY3437943) is Eli Lilly’s investigational GIP, GLP-1 and glucagon receptor triple agonist. It is in phase 3 trials and is not approved anywhere. Research-market vials, often listed under the catalog name GLP-3, ship as lyophilized powder that has to be dissolved before it can be measured, and turning a labelled 10 mg vial and a syringe of bacteriostatic water into “units on an insulin syringe” is where most of the mistakes happen. This retatrutide dosage calculator does that arithmetic, shows every intermediate step, and draws the result on a syringe so the number can be checked against the barrel.
WHAT THIS TOOL IS, AND IS NOT
It converts the vial size and water volume you enter into a concentration, and converts an amount you choose into insulin-syringe units. Nothing is pre-filled as a dose and nothing on this page recommends one. Retatrutide is an investigational drug; no dose outside a supervised trial has been established, and the trial doses are listed further down as context only.
How the retatrutide math works
Three steps, and every peptide calculator uses the same three. First, concentration: milligrams in the vial divided by millilitres of bacteriostatic water added gives mg/mL. A 10 mg vial with 2 mL of water is 5 mg/mL. Second, what one syringe unit holds: a U-100 insulin syringe has 100 units per millilitre, so one unit is 0.01 mL, and the amount in one unit is the concentration divided by 100 (in mg) or multiplied by 10 (in mcg). At 5 mg/mL, one unit holds 50 mcg. Third, units to draw: the amount you chose, in mcg, divided by the mcg in one unit.
Two practical consequences fall out of that arithmetic. Adding more water lowers the concentration, so any given amount becomes more units and is easier to read on the syringe; adding less water does the opposite and can push an amount below two units, where the markings stop being precise. And the vial’s total content sets a hard ceiling: it does not matter how it is diluted, a 10 mg vial only ever contains 10 mg.
Retatrutide reconstitution chart
The same arithmetic laid out for the vial sizes retatrutide is commonly sold in, at one, two and three millilitres of bacteriostatic water. “Per unit” is one mark on a U-100 insulin syringe; “per 10 units” is 0.1 mL. These are conversions, not doses.
| Vial | Water added | Concentration | Per unit | Per 10 units |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 50 mcg | 500 mcg |
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg | 250 mcg |
| 5 mg | 3 mL | 1.667 mg/mL | 16.67 mcg | 166.7 mcg |
| 10 mg | 1 mL | 10 mg/mL | 100 mcg | 1,000 mcg |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg | 500 mcg |
| 10 mg | 3 mL | 3.333 mg/mL | 33.33 mcg | 333.3 mcg |
| 15 mg | 1 mL | 15 mg/mL | 150 mcg | 1,500 mcg |
| 15 mg | 2 mL | 7.5 mg/mL | 75 mcg | 750 mcg |
| 15 mg | 3 mL | 5 mg/mL | 50 mcg | 500 mcg |
| 20 mg | 1 mL | 20 mg/mL | 200 mcg | 2,000 mcg |
| 20 mg | 2 mL | 10 mg/mL | 100 mcg | 1,000 mcg |
| 20 mg | 3 mL | 6.667 mg/mL | 66.67 mcg | 666.7 mcg |
| 30 mg | 1 mL | 30 mg/mL | 300 mcg | 3,000 mcg |
| 30 mg | 2 mL | 15 mg/mL | 150 mcg | 1,500 mcg |
| 30 mg | 3 mL | 10 mg/mL | 100 mcg | 1,000 mcg |
Table values are exact arithmetic (mg ÷ mL; mcg per unit = mg/mL × 10). They assume the vial label is accurate, which for research-market products is only established by a batch-matched certificate of analysis.
What the retatrutide trials administered
Every published retatrutide trial used a once-weekly subcutaneous injection of a pharmaceutical formulation supplied by the sponsor, Eli Lilly, with dose escalation over the opening weeks and medical monitoring throughout. The table is reproduced so that readers know what the evidence actually covers. It is not a schedule for anyone to follow, and none of these figures is entered into the calculator for you.
| Trial | Population | Weekly maintenance doses | Duration | Source |
|---|---|---|---|---|
| Phase 2 obesity (Jastreboff 2023, NEJM) | 338 adults with obesity, or overweight plus a weight-related condition | 1, 4, 8 and 12 mg (the 4 mg and 8 mg arms started at 2 or 4 mg; 12 mg started at 2 mg) | 48 weeks | PMID 37366315 |
| Phase 2 type 2 diabetes (Rosenstock 2023, Lancet) | 281 adults with type 2 diabetes | 0.5, 4, 8 and 12 mg (escalation arms started at 2 or 4 mg; one 4 mg arm had no escalation) | 36 weeks | PMID 37385280 |
| MASLD substudy (Sanyal 2024, Nat Med) | 98 participants of the obesity trial with at least 10% liver fat | 1, 4, 8 and 12 mg | 48 weeks | PMID 38858523 |
| Phase 3 TRANSCEND-T2D-1 (Bajaj 2026, Lancet) | 537 adults with type 2 diabetes on diet and exercise alone | 4, 9 and 12 mg | 40 weeks | PMID 42250575 |
Three things in that table matter to anyone holding a calculator. First, the range is wide: 0.5 mg to 12 mg a week is a 24-fold spread, and outcomes scaled with it; weight change at 48 weeks in the obesity trial ran from −8.7% in the 1 mg group to −24.2% in the 12 mg group. Second, in both phase 2 trials no arm began at a maintenance dose above 4 mg. The 8 mg and 12 mg groups reached those levels by escalation, and the NEJM investigators reported that gastrointestinal side effects “were partially mitigated with a lower starting dose (2 mg vs. 4 mg)”. Third, the phase 3 programme settled on 4, 9 and 12 mg, so the 9 mg figure that turns up in newer discussions comes from TRANSCEND, not from the phase 2 work.
What is not in the table: any trial of reconstituted lyophilized retatrutide from a research vendor, any data on how long a reconstituted vial keeps, and any dose studied outside a monitored protocol. For the adverse-event rates behind these arms, see our retatrutide side effects page, which is built from the same abstracts.
Reconstitution notes that change the numbers
Bacteriostatic water, not sterile water, for multi-draw vials. Bacteriostatic water contains 0.9% benzyl alcohol, which is what allows a reconstituted vial to be entered more than once; sterile water has no preservative. Our bacteriostatic water guide covers the label facts.
Volume added is the number that matters, not the vial’s stated capacity. If you add 2 mL, the concentration uses 2 mL regardless of whether the water vial says 10 mL or 30 mL. Measure the water with the same insulin syringe you will draw with, since 100 units is 1 mL.
Lyophilized powder adds a negligible volume. A few milligrams of peptide dissolved in millilitres of water does not change the volume in a way an insulin syringe can resolve, which is why every calculator, including this one, ignores it.
Label accuracy is the biggest error term. A vial labelled 10 mg that assays at 80% of label contains 8 mg of the stated compound, and every number above shifts with it. This is why a recent, batch-matched third-party certificate of analysis is the minimum standard on Peptide Insider, and why we publish how to read one.
Frequently asked questions
Does this calculator recommend a retatrutide dose?
No. The amount field is empty until you type into it, and the page never fills it. The calculator converts the vial size and water volume you enter into a concentration, then converts the amount you choose into syringe units. What the trials administered is described on this page as context, with the source abstracts linked, and not as a recommendation.
How many units is 1 mg of retatrutide?
It depends entirely on the concentration, which is why the question has no fixed answer. As arithmetic: a 10 mg vial dissolved in 2 mL is 5 mg/mL, so 1 mg is 0.2 mL, which is 20 units on a U-100 insulin syringe. The same vial in 1 mL is 10 mg/mL, and 1 mg becomes 10 units. Change the water, and every unit figure changes with it.
Is GLP-3 the same thing as retatrutide?
Yes. GLP-3 is a catalog name some research vendors use for retatrutide; it is not a separate compound and there is no hormone called GLP-3. The vial label may read either name. Our GLP-3 buying guide covers the naming and the vendors that use it.
Why does research-market retatrutide come as a powder when the trials used a ready-made injection?
The trials used a pharmaceutical formulation manufactured by the sponsor. Research vendors sell the peptide as a lyophilized (freeze-dried) powder because it is more stable to ship and store that way, and the buyer reconstitutes it. That step is exactly where a calculator is needed, and it is also a step that no published trial has studied.
Which syringe size should I select?
Select the syringe you actually have. All three options are U-100 insulin syringes, so one unit is 0.01 mL on each; the 30, 50 and 100 choices only change the capacity ceiling and how the drawing is scaled. The calculator warns you when an amount exceeds the syringe you selected or falls below two units, where the markings stop being precise.
What happens if I enter more water than the vial can hold?
The arithmetic still works, because concentration is simply milligrams divided by millilitres, but a real vial has a physical fill limit that the label does not always state. The reconstitution chart therefore stops at 5 mL, and the calculator flags concentrations above 10 mg/mL as unusually strong, since very small water volumes make every unit carry a lot of peptide and magnify any measuring error.